# Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

> **NCT01193699** · PHASE1,PHASE2 · COMPLETED · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 24 (estimated)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** PEG-P-INF alpha-2b (P1101)

## Key facts

- **NCT ID:** NCT01193699
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2018-01-25
- **Final completion:** 2018-01-25
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193699, "Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT01193699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*